Bevenopran
Bevenopran (INN, USAN) (former developmental code names CB-5945, ADL-5945, MK-2402, OpRA III) is a peripherally acting μ-opioid receptor antagonist that also acts on δ-opioid receptors and was under development by Cubist Pharmaceuticals for the treatment of chronic opioid-induced constipation. It reached phase III clinical trials for this indication before being discontinued. See also * Alvimopan * Axelopran * Eluxadoline * Methylnaltrexone * Naldemedine * Naloxegol Naloxegol (INN; PEGylated naloxol; trade names Movantik and Moventig) is a peripherally acting μ-opioid receptor antagonist developed by AstraZeneca, licensed from Nektar Therapeutics, for the treatment of opioid-induced constipation. It was a ... References Amines Carboxamides Drugs acting on the gastrointestinal system and metabolism Laxatives Mu-opioid receptor antagonists Peripherally selective drugs Pyrazines {{gastrointestinal-drug-stub ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]